Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 12 (December)

1. From a pump handle to oral rehydration therapy: a model of translational research.
   Adv Physiol Educ, 31(4): 288-93. [Abstract] [Full-text]
2. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
   Ophthalmology, 114(12): 2183-9. [Abstract] [Full-text]
3. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
   Lancet Oncol, 8(12): 1071-8. [Abstract] [Full-text]
4. Evaluating the clinical appropriateness of nurses' prescribing practice: method development and findings from an expert panel analysis.
   Qual Saf Health Care, 16(6): 415-21. [Abstract] [Full-text]
5. The association of asthma, atopy and lung function with hormone replacement therapy and surgical cessation of menstruation in a population-based sample of English women.
   Allergy, 63(1): 95-102. [Abstract] [Full-text]
6. Oral contraceptive use, hormone replacement therapy, reproductive history and risk of colorectal cancer in women.
   Int J Cancer, 122(3): 643-6. [Abstract] [Full-text]
7. Three-dimensional fibrous PLGA/HAp composite scaffold for BMP-2 delivery.
   Biotechnol Bioeng, 99(1): 223-34. [Abstract] [Full-text]
8. New developments in the diagnosis and management of pediatric UTIs.
   Urol Clin North Am, 35(1): 47-58; vi. [Abstract] [Full-text]
9. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
   Onkologie, 30(12): 637-43. [Abstract] [Full-text]
10. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
    Onkologie, 30(12): 629-35. [Abstract] [Full-text]
11. Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival.
    Onkologie, 30(12): 611-7. [Abstract] [Full-text]
12. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?
    J Clin Oncol, 25(35): 5649-54. [Abstract] [Full-text]
13. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    J Clin Oncol, 25(35): 5597-602. [Abstract] [Full-text]
14. From bench to bedside: successful translational nanomedicine: highlights of the Third Annual Meeting of the American Academy of Nanomedicine.
    Nanomedicine, 3(4): 322-31. [Abstract] [Full-text]
15. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Nanomedicine, 3(4): 246-57. [Abstract] [Full-text]
16. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin.
    Nanomedicine, 3(4): 258-65. [Abstract] [Full-text]
17. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process.
    Nanomedicine, 3(4): 273-80. [Abstract] [Full-text]
18. Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles.
    J Control Release, 125(1): 59-67. [Abstract] [Full-text]
19. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection.
    J Control Release, 125(1): 68-75. [Abstract] [Full-text]
20. Polymer blends for controlled release coatings.
    J Control Release, 125(1): 1-15. [Abstract] [Full-text]
21. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na+/glucose cotransporter (SGLT1) in the small intestine.
    J Control Release, 125(1): 42-9. [Abstract] [Full-text]
22. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. pylori.
    J Control Release, 125(1): 33-41. [Abstract] [Full-text]
23. Thermally sensitive cationic polymer nanocapsules for specific cytosolic delivery and efficient gene silencing of siRNA: swelling induced physical disruption of endosome by cold shock.
    J Control Release, 125(1): 25-32. [Abstract] [Full-text]
24. Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles.
    J Control Release, 125(1): 50-8. [Abstract] [Full-text]
25. Optimization of HAART with genetic algorithms and agent-based models of HIV infection.
    Bioinformatics, 23(24): 3350-5. [Abstract] [Full-text]
26. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Pediatr Blood Cancer, 50(2): 386-8. [Abstract] [Full-text]
27. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
    Pediatr Blood Cancer, 50(2): 312-8. [Abstract] [Full-text]
28. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 50(2): 259-63. [Abstract] [Full-text]
29. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group.
    Pediatr Blood Cancer, 50(2): 236-41. [Abstract] [Full-text]
30. Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group.
    Pediatr Blood Cancer, 50(2): 242-5. [Abstract] [Full-text]
31. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy.
    Pediatr Blood Cancer, 50(2): 308-11. [Abstract] [Full-text]
32. Nutrient mixture including vitamin C, L-lysine, L-proline, and epigallocatechin is ineffective against tumor growth and metastasis in a syngeneic neuroblastoma model.
    Pediatr Blood Cancer, 50(2): 284-8. [Abstract] [Full-text]
33. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study.
    Pediatr Blood Cancer, 50(2): 227-30. [Abstract] [Full-text]
34. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
    Pediatr Blood Cancer, 50(2): 223-6. [Abstract] [Full-text]
35. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis.
    Pediatr Blood Cancer, 50(2): 246-9. [Abstract] [Full-text]
36. Full-dose ifosfamide can be safely administered to outpatients.
    Pediatr Blood Cancer, 50(2): 375-8. [Abstract] [Full-text]
37. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic.
    Biophys J, 94(1): 173-81. [Abstract] [Full-text]
38. Intermediate-term outcome of the simplified laparoscopic antegrade continence enema procedure: less is better.
    J Urol, 179(1): 299-303. [Abstract] [Full-text]
39. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    J Urol, 179(1): 163-6. [Abstract] [Full-text]
40. Intravenous fluid administration in elderly patients at a London hospital: a two-part audit encompassing ward-based fluid monitoring and prescribing practice by doctors.
    Int J Surg, 5(6): 408-12. [Abstract] [Full-text]
41. Five day antibiotic prophylaxis for major lower limb amputation reduces wound infection rates and the length of in-hospital stay.
    Eur J Vasc Endovasc Surg, 35(1): 75-8. [Abstract] [Full-text]
42. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Am Heart J, 155(1): 133-9. [Abstract] [Full-text]
43. Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial.
    Am Heart J, 155(1): 121-7. [Abstract] [Full-text]
44. Comparing invasive and noninvasive management strategies for acute myocardial infarction using administrative databases.
    Am Heart J, 155(1): 42-8. [Abstract] [Full-text]
45. Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
    Am Heart J, 155(1): 19-25. [Abstract] [Full-text]
46. Hormone replacement therapy use and variations in the risk of breast cancer.
    BJOG, 115(2): 169-75; discussion 175. [Abstract] [Full-text]
47. Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity.
    Biochem Biophys Res Commun, 365(4): 801-7. [Abstract] [Full-text]
48. Systematic review of the literature for the use of oesophageal Doppler monitor for fluid replacement in major abdominal surgery.
    Anaesthesia, 63(1): 44-51. [Abstract] [Full-text]
49. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Circulation, 116(25): 2923-32. [Abstract] [Full-text]
50. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.
    BJU Int, 101(1): 20-5. [Abstract] [Full-text]
51. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review.
    J Clin Oncol, 25(36): 5808-14. [Abstract] [Full-text]
52. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.
    J Clin Oncol, 25(36): 5800-7. [Abstract] [Full-text]
53. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
    J Clin Oncol, 25(36): 5777-84. [Abstract] [Full-text]
54. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    J Clin Oncol, 25(36): 5742-7. [Abstract] [Full-text]
55. Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction.
    Nat Clin Pract Cardiovasc Med, 5(1): 42-52. [Abstract] [Full-text]
56. Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication.
    AJR Am J Roentgenol, 190(1): 187-90. [Abstract] [Full-text]
57. Hepatic arterial chemoembolization for management of metastatic melanoma.
    AJR Am J Roentgenol, 190(1): 99-104. [Abstract] [Full-text]
58. Extending the light-harvesting properties of transition-metal dendrimers.
    Chemphyschem, 8(18): 2643-51. [Abstract] [Full-text]
59. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension.
    Hypertension, 51(1): 69-76. [Abstract] [Full-text]
60. Novel molecules for intra-oral delivery of antimicrobials to prevent and treat oral infectious diseases.
    Biochem J, 409(2): 601-9. [Abstract] [Full-text]
61. Treatment of metastatic urachal carcinoma in an elderly woman.
    Nat Clin Pract Oncol, 5(1): 55-8. [Abstract] [Full-text]
62. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.
    Nat Clin Pract Oncol, 5(1): 44-54. [Abstract] [Full-text]
63. Current optimal chemotherapy for advanced urothelial cancer.
    Expert Rev Anticancer Ther, 8(1): 51-61. [Abstract] [Full-text]
64. Role of triptolide as an adjunct chemotherapy for ovarian cancer.
    Chemotherapy, 54(1): 67-76. [Abstract] [Full-text]
65. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
    Chemotherapy, 54(1): 54-62. [Abstract] [Full-text]
66. Intranasal mupirocin prophylaxis in elective surgery. A review of published studies.
    Chemotherapy, 54(1): 9-16. [Abstract] [Full-text]
67. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.
    Am J Respir Crit Care Med, 177(1): 108-13. [Abstract] [Full-text]
68. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?
    AIDS, 22(2): 269-73. [Abstract] [Full-text]
69. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
    Br J Ophthalmol, 92(1): 74-5. [Abstract] [Full-text]
70. Incidence of postoperative hyponatremia and complications in critically-ill children treated with hypotonic and normotonic solutions.
    J Pediatr, 152(1): 33-8. [Abstract] [Full-text]
71. Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial.
    Eur J Surg Oncol, 34(1): 30-5. [Abstract] [Full-text]
72. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
    Eur J Surg Oncol, 34(1): 6-12. [Abstract] [Full-text]
73. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000).
    Am J Ophthalmol, 145(1): 12-22. [Abstract] [Full-text]
74. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994).
    Am J Ophthalmol, 145(1): 5-11. [Abstract] [Full-text]
75. A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora.
    Am J Ophthalmol, 145(1): 136-142. [Abstract] [Full-text]
76. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment.
    Biotechnol Bioeng, 99(2): 442-54. [Abstract] [Full-text]
77. The use of peptide-delivery to protect human adipose-derived adult stem cells from damage caused by the internalization of quantum dots.
    Biomaterials, 29(7): 925-36. [Abstract] [Full-text]
78. CD200: a putative therapeutic target in cancer.
    Biochem Biophys Res Commun, 366(1): 117-22. [Abstract] [Full-text]
79. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI.
    Biotechnol Bioeng, 99(3): 721-7. [Abstract] [Full-text]
80. Drug-related problems in hospitalized patients with HIV infection.
    Am J Health Syst Pharm, 65(1): 55-9. [Abstract] [Full-text]
81. Enhanced photoemission spectroscopy for verification of high-risk i.v. medications.
    Am J Health Syst Pharm, 65(1): 49-54. [Abstract] [Full-text]
82. Recent developments in the management of acute respiratory distress syndrome in adults.
    Am J Health Syst Pharm, 65(1): 29-36. [Abstract] [Full-text]
83. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
    Biol Blood Marrow Transplant, 14(1): 59-66. [Abstract] [Full-text]
84. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    J Med Virol, 80(2): 209-16. [Abstract] [Full-text]
85. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    N Engl J Med, 357(26): 2666-76. [Abstract] [Full-text]
86. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Pediatr Infect Dis J, 27(1): 17-21. [Abstract] [Full-text]
87. Towards the reduction of medication errors in orthopedics and spinal surgery: outcomes using a pharmacist-led approach.
    Spine, 33(1): 104-7. [Abstract] [Full-text]
88. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Gynecol Oncol, 108(1): 201-6. [Abstract] [Full-text]
89. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Gynecol Oncol, 108(1): 226-33. [Abstract] [Full-text]
90. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
    Gynecol Oncol, 108(1): 130-5. [Abstract] [Full-text]
91. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
    Gynecol Oncol, 108(1): 195-200. [Abstract] [Full-text]
92. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
    Gynecol Oncol, 108(1): 166-72. [Abstract] [Full-text]
93. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Gynecol Oncol, 108(1): 90-4. [Abstract] [Full-text]
94. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Gynecol Oncol, 108(1): 136-40. [Abstract] [Full-text]
95. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.
    Gynecol Oncol, 108(1): 58-62. [Abstract] [Full-text]
96. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
    Gynecol Oncol, 108(1): 149-53. [Abstract] [Full-text]
97. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Gynecol Oncol, 108(1): 100-5. [Abstract] [Full-text]
98. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Gynecol Oncol, 108(1): 47-52. [Abstract] [Full-text]
99. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Gynecol Oncol, 108(1): 68-71. [Abstract] [Full-text]
100. A needed information source.
     Clin Pharmacol Ther, 83(1): 22-3. [Abstract] [Full-text]
101. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
     J Clin Oncol, 26(1): 127-31. [Abstract] [Full-text]
102. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
     J Clin Oncol, 26(1): 76-82. [Abstract] [Full-text]
103. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
     J Clin Oncol, 26(1): 60-5. [Abstract] [Full-text]
104. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
     J Clin Oncol, 26(1): 54-9. [Abstract] [Full-text]
105. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
     J Clin Oncol, 26(1): 44-53. [Abstract] [Full-text]
106. Drug safety in pregnant women and their babies: ignorance not bliss.
     Clin Pharmacol Ther, 83(1): 181-3. [Abstract] [Full-text]
107. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora.
     J Control Release, 125(2): 77-86. [Abstract] [Full-text]
108. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats.
     J Control Release, 125(2): 121-30. [Abstract] [Full-text]
109. Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates?
     J Control Release, 125(2): 87-95. [Abstract] [Full-text]
110. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
     J Clin Oncol, 26(1): 37-43. [Abstract] [Full-text]
111. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
     J Clin Oncol, 26(1): 90-5. [Abstract] [Full-text]
112. Improving women's health through modernization of our bioinformatics infrastructure.
     Clin Pharmacol Ther, 83(1): 192-5. [Abstract] [Full-text]
113. Pharmacokinetic studies in pregnant women.
     Clin Pharmacol Ther, 83(1): 184-7. [Abstract] [Full-text]
114. Comparison of three perioperative fluid regimes for laparoscopic donor nephrectomy : A prospective randomized dose-finding study.
     Surg Endosc, 22(1): 146-50. [Abstract] [Full-text]
115. Surfactant-promoted formation of fractal and dendritic nanostructures of gold and silver at the organic-aqueous interface.
     J Colloid Interface Sci, 318(2): 501-6. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.